Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Clinical trial NCT06543069 · RECRUITING
Trial details
- NCT number
- NCT06543069
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-31
- Primary completion
- 2026-01-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.